Oral semaglutide also demonstrated a favorable cardiovascular safety profile, and significant reductions in cardiovascular death and all-cause mortality vs
Pinto, M., Brennan, L., Diehl, K., Lin, S., Heacock, S
According to the report, Harlan Krumholz, a professor of medicine at Yale University who edits the Journal of the American College of Cardiology where the studies were published, said that the drug was "somehow quieting inflammation," adding that the benefit was "broad there's not a group that doesn't seem to be benefiting." "Is it a fountain of youth I would say if you're improving someone's cardiometabolic health substantially, then you are putting them in a position to live longer and better," he continued
Even when insurance partially covers the drug, long-term treatment can become financially difficult